NCT01782690View on ClinicalTrials.gov

An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

CompletedOBSERVATIONAL
Enrollment

338

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Pancreatic Cancer
Interventions
DRUG

erlotinib

Study participants will receive erlotinib according to Summary of Product Characteristics (SmPC)

DRUG

gemcitabine

Study participants will receive gemcitabine according to Summary of Product Characteristics (SmPC)

Trial Locations (1)

50937

Klinikum der Universität zu Köln Klinik für Gastroenterologie am Abdominalzentrum, Cologne

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01782690 - An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter